POLTREG S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.7 PLN | +7.11% |
|
-0.64% | -6.22% |
| May. 23 | Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 18 | Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 42M 10.53M | Sales 2025 * | 14M 3.51M | Capitalization | 218M 54.59M |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 752K | Net income 2025 * | -12M -3.01M | EV / Sales 2024 * | 5.19 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 15.6 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 23 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.67% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +7.11% | ||
| 1 week | -0.64% | ||
| Current month | -0.64% | ||
| 1 month | -3.71% | ||
| 3 months | -14.78% | ||
| 6 months | -10.19% | ||
| Current year | -6.22% |
1 week
43.40
47.00
1 month
43.4049.50
Current year
43.4057.80
1 year
43.4065.00
3 years
30.1073.90
5 years
30.1073.90
10 years
30.1073.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14-12-31 | |
| Director of Finance/CFO | - | 23-02-28 | |
Marta Druch
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 21-05-20 | |
| Director/Board Member | 49 | 21-07-14 | |
| Chairman | - | 21-05-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 46.7 | +7.11% | 391 |
| 24-06-06 | 43.6 | -6.44% | 572 |
| 24-06-05 | 46.6 | +1.30% | 704 |
| 24-06-04 | 46 | -1.29% | 183 |
| 24-06-03 | 46.6 | -0.85% | 140 |
Delayed Quote Warsaw S.E., June 07, 2024 at 11:55 am EDT
More quotes
Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
46.7
PLN
Average target price
68.2
PLN
Spread / Average Target
+46.04%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.22% | 54.6M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- PTG Stock
